Shanghai Pharmaceutical Accelerates Retail Restructuring
This article was originally published in PharmAsia News
Executive SummaryAs part of its restructuring, Shanghai Pharmaceutical (Group) has started consolidating since January its three major pharmaceutical retail companies - Sine Pharmacy, Leiyunshang Pharmacy and Huashi Pharmacy. As the flagship brand, Huashi Pharmacy will serve as the consolidation platform, overseeing Sine and Leiyunshang Pharmacy. Meanwhile, Shanghai Pharma is pumping assets into Huashi to increase the latter's capital. An inside source disclosed that the group's plan for the next three years focuses on accelerating the development of its direct pharmaceutical retail chain business. According to the three-step program, Shanghai Pharma will first complete integration of the group's internal retail business within 2009; it will then adopt a development model of direct selling stores, followed by ways of exploring international collaborations. (Click here for more - Chinese Language)
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.